Afya Limited
AFYA scores 47.2 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -15.0 points significantly impact the ranking. Without these adjustments, AFYA would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| AFYA | 47.2 | 9.1 | 14.9% | 20.1% | $1.2B |
| MNST | 84.4 | 46.3 | 4.9% | 20.1% | $84.6B |
| COCO | 77.4 | 43.1 | 18.2% | 11.7% | $3.3B |
| CALM | 76.7 | 3.5 | 83.2% | 27.4% | $4.1B |
| LAUR | 76.3 | 25.8 | 5.5% | 18.9% | $4.9B |
| WMT | 71.5 | 46.7 | 5.1% | 2.9% | $1.0T |
| CCEP | 68.9 | 25.1 | 11.7% | 6.9% | $49.7B |
| PSMT | 66.5 | 31.5 | 7.2% | 2.7% | $4.8B |
| COST | 66.2 | 54.6 | 8.2% | 2.9% | $441.9B |
| PEP | 65.1 | 27.6 | 2.3% | 8.8% | $230.9B |
| COKE | 64.6 | 23.1 | 3.7% | 9.2% | $16.7B |
| PRDO | 64.0 | 13.1 | 24.2% | 18.9% | $2.2B |
| SFD | 63.8 | 11.3 | -3.4% | 5.5% | $9.6B |
| OLLI | 62.5 | 31.4 | 8.0% | 8.8% | $6.7B |
| FIZZ | 61.2 | 18.6 | 0.8% | 15.6% | $3.5B |
| DLTR | 61.0 | 23.9 | 4.8% | 5.9% | $25.7B |
| Sector Average | 51.1 | 33.1 | 10.6% | -3.2% | โ |
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
Stage 4 downtrend โ price is below both SMA50 and SMA200 with a declining 200-day average. Capital preservation takes priority. Do not buy into a downtrend.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $929M | $919M | $936M | $849M |
| Gross Profit | $589M | $577M | $654M | $542M |
| Operating Income | $277M | $285M | $373M | $258M |
| Net Income | $155M | $172M | $252M | $150M |
| EPS (Diluted) | $1.70 | $1.88 | $2.76 | $1.65 |
| Gross Margin | 63.4% | 62.7% | 69.8% | 63.8% |
| Operating Margin | 29.9% | 31.0% | 39.8% | 30.4% |
| Net Margin | 16.7% | 18.7% | 26.9% | 17.7% |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor โ it is a practical tradability overlay).
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $12.62 | $28.23 | 76.4% | Wide |
| 2022 | $8.73 | $17.02 | 64.4% | Wide |
| 2023 | $9.66 | $22.41 | 79.5% | Wide |
| 2024 | $14.52 | $22.48 | 43% | Wide |
| 2025 | $13.47 | $19.90 | 38.5% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.